CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 437 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01902628
NCT01902628N/ACompleted

An Observational, Prospective Study to Evaluate the Hemoglobin Levels in Non-Dialysis Chronic Kidney Disease Subjects With Renal Anemia, Treated With MIRCERA (Methoxy-Polyethylene-Glycol-Epoetin Beta)

Hoffmann-La Roche·observational·Posted Jul 18, 2013·Updated Aug 9, 2019

In Brief

An observational study for Anemia. Completed, enrolled 437 participants across 24 sites.

Detailed Summary

This prospective observational study evaluated the efficacy and safety of Mircera (methoxy polyethylene glycol-epoetin beta) in chronic kidney disease participants on dialysis with renal anemia. Participants initiated on treatment with Mircera according to the Summary of Product Characteristics and standard clinical practice were followed for 10 months.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAnemia
CountriesGreece
Collaborators--

Timeline

N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJul 18, 2013
Enrollment StartJul 15, 2013
Primary CompletionSep 4, 2016
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 13.0 years ago